Workflow
化橘红饮片
icon
Search documents
ST香雪及其子公司涉及诉讼金额累计超九千万元
Jing Ji Guan Cha Wang· 2026-02-09 13:46
Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue) is facing multiple challenges, with over 92.26 million yuan in litigation amounts disclosed in the past year, accounting for 8.78% of the company's latest audited net assets [2] - The company has been involved in significant legal disputes, including a contract dispute amounting to 20.92 million yuan and a financial loan dispute totaling 44.96 million yuan [2] - Established in 1986, ST Xiangxue has developed a full industry chain from traditional Chinese medicine cultivation to production and distribution, with core products including medicinal syrups and granules [2] Financial Performance - Since 2016, ST Xiangxue's net profit has declined significantly, with a drop of over 60% in 2016 to 66.02 million yuan, and subsequent years maintaining net profits between 60 million and 70 million yuan [3] - The company reported a loss of 677 million yuan in 2021, followed by losses of 530 million yuan, 389 million yuan, and 859 million yuan in 2022, 2023, and 2024 respectively [3] - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [3] Restructuring Efforts - The pre-restructuring process was approved by the Guangzhou Intermediate People's Court, initially set for three months but has faced multiple extensions, now extended to January 11, 2026 [3][4] - Despite ongoing restructuring efforts, the company projected a significant loss for 2025, estimating a net loss between 635 million yuan and 934 million yuan [4] - Contributing factors to the losses include intensified market competition, liquidity issues, high financial costs, and asset impairment provisions totaling approximately 130 million yuan [4][5]
ST香雪深陷多重危机
Jing Ji Guan Cha Wang· 2026-02-09 11:36
作为一家成立于1986年的老牌中药企业,香雪制药在2010年12月于深交所上市。公司名称取自广州著名景点萝岗香雪。近年来,香雪制药致力于打造从中药 材种植到医药流通的全产业链布局,并开发了包括中药饮片、中成药、医疗器械和T细胞免疫治疗在内的多系列产品。 广州市香雪制药股份有限公司(证券代码:ST香雪,300147.SZ)近期陷入多重困境。根据最新公告,该公司及其子公司在过去一年中涉及的诉讼金额已超 过九千万元。截至2月8日,公司及子公司的诉讼案件累计金额约为9226.56万元,占其最近一期经审计净资产的8.78%。 除了小额案件外,主要的诉讼包括与广州万博佳诚创业投资合作企业之间的合同纠纷,涉案金额达2,092万元,以及与某银行金融借贷纠纷,涉案金额高达 4,496万元。由于部分案件仍在审理或未结案,具体的诉讼影响尚待进一步评估,因此对公司当期及未来的利润影响仍不确定。 公司动态 与此同时,香雪制药在2025年的业绩预告显示,预计全年归母净利润将亏损6.35亿元至9.34亿元,扣非净利润亏损6.12亿元至8.99亿元。造成这一亏损的主要 原因包括市场竞争加剧、流动性危机导致的收入减少和毛利率下降,以及高额的财 ...
老牌中药企业香雪制药陷困境:涉讼金额超九千万,正推动预重整
Jing Ji Guan Cha Wang· 2026-02-09 10:26
公告称,上市公司及子公司涉及的诉讼,鉴于部分案件尚在法院审理中或尚未结案,案件影响金额尚需 进一步评估,诉讼案件对公司本期及期后利润的影响尚无法判断,具体以公司经审计的财务报告为准。 老牌中药企业广州市香雪制药股份有限公司(证券简称:ST香雪(300147),300147.SZ)身陷多重困 境,根据最新披露,上市公司及子公司过去一年涉讼金额超过九千万元。 据ST香雪2月8日公告,截至公告披露日,除已经披露的诉讼事项外,公司及子公司连续十二个月内作 为被告累计涉及的诉讼事项涉案金额合计约9226.56万元,占最近一期经审计净资产8.78%。除几万元至 几十万元的小额案件外,公司与广州万博佳诚创业投资合作企业的合同纠纷涉案金额达到2,092万元, 与中国农业银行股份有限公司化州市支行的金融借贷纠纷涉案金额达到4,496万元。 (经济观察网杜远/文) 上市初期的香雪制药净利润规模一度超过1亿元,但2016年后公司业绩开始下滑。2016年公司净利润同 比下跌超六成,为6602.41万元,2016年—2020年,公司净利润规模保持在6000万元-7000万元规模, 2021年则由盈转亏,当年出现大额亏损6.77亿元。2 ...
全国劳模廖志略:十年兴农路 推动化橘红结出百亿硕果
Core Viewpoint - The article highlights the successful transformation of the Huazhou Huajuhong industry through innovative marketing strategies, particularly the use of short dramas and live streaming, which significantly boosted sales and attracted young talent back to the region [1][4]. Group 1: Industry Development - The Huajuhong industry achieved a sales revenue of nearly 260 million yuan, driven by a short drama that creatively combined historical and modern elements [1]. - The industry has grown to exceed 10 billion yuan in value, with over 35,000 individuals engaged in Huajuhong-related activities [3][8]. - The area under Huajuhong cultivation has surpassed 130,000 acres, with an annual production of over 60,000 tons of fresh fruit and 12,000 tons of dried fruit [8]. Group 2: Innovation and Marketing - The introduction of the short drama "Huazhou Huajuhong, the First Red in the World" effectively reached over 100 million users globally, converting viewership into consumer interest [4]. - The cooperative has developed over 20 processed products, including herbal slices and throat lozenges, expanding the application of Huajuhong [8]. - The cooperative's innovative marketing strategies, including e-commerce and live streaming, have successfully increased market awareness and sales [6][8]. Group 3: Community Impact - The cooperative model has created a multi-dimensional support system for farmers, benefiting 15,000 households through guaranteed purchase agreements [8]. - Over 3,000 farmers have been uplifted economically through the cooperative's initiatives, contributing to local employment and income generation [1][8]. - The establishment of a Huajuhong museum and advocacy for its cultural heritage aims to promote the product internationally [5].